Please find below, in the File(s) section of this page, the presentations featured at the DTN-UK Team Education Day 2023.

The 2023 Endocrinology & Diabetes Specialty Certificate Examination is proceeding as scheduled on 14th June 2023.
 

EXTOD Conference returns in 2023 with a new and extended format. 

This two day conference will cover the core learning of previous EXTOD conferences, and will also offer an advanced second day to build on foundation knowledge. 

Delegates can choose to book one or two days (please note that in order to book Day 2 (Advanced) you will have needed to have previously attended an EXTOD conference)

Quality in Care (QiC) Diabetes are the prestigious UK & Ireland awards, which since 2011 have been recognising, rewarding and sharing initiatives that improve the quality of life for people living with diabetes.

Exceptional work has been undertaken in treatment and options available for people with diabetes and/or their families/carers. The awards are a way to recognise this outstanding work.

The Department of Health and Social Care has issued a medicines supply notice (MSN) confirming that Novo Nordisk’s Tresiba® U100 FlexTouch® disposable insulin pen is expected to be out of stock within the UK from the beginning of August. This does not affect presentations of Tresiba in other devices or doses.

This MSN follows the notice earlier this week regarding a temporary shortage of the GlucaGen® (glucagon) HypoKit®.

The Department of Health and Social Care (DHSC) has published a Medicines Shortage Notification (MSN/2023/051) confirming that Novo Nordisk’s GlucaGen® (glucagon) HypoKit® is in short supply and making recommendations to healthcare professionals about action they can take as a result to support patients.  

Improvement in renal function in chronic kidney disease in the first UK National Health Service (NHS) EndoBarrier service for uncontrolled diabesity

Authors:

REJ Ryder, P Sen Gupta, M Yadagiri, SP Irwin, W Burbridge, T Bashir, RA Allden, JP Bleasdale, EN Fogden, M Anderson and P Cockwell.

EndoBarrier treatment for longstanding type 2 diabetes and obesity: A comparison of the outcomes with an implantation period of 9 months versus 12 months in 90 consecutive EndoBarrier treated patients RESULTS Table 1: 78/90 (87%) patients attended review at both 9-months and 12-months after EndoBarrier implantation. Baseline characteristics: .

Authors: REJ Ryder, M Yadagiri, W Burbridge, SP Irwin, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta.